Editorial
Liquid biopsy guided precision therapy for lung cancers
Abstract
Wang et al. reported results of the BENEFIT trial sponsored by Chinese Thoracic Oncology Group (CTONG) in Lancet Respiratory Medicine, the first clinical trial conducted using circulating tumor DNA (ctDNA) for patient selection (1).
